Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02296580 : A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Subject has histologically confirmed diagnosis of GBM.

- Subject has failed or intolerant to radiotherapy.

- Subjects has failed or intolerant to temozolomide therapy.

- Subject has progressive disease with at least one measureable lesion on MRI.

- Subject is at least 18 years of age.

- Subject has a KPS = 60.

- Subject has adequate organ and marrow function.

Exclusion Criteria:

- Subject has received bevacizumab (Avastin).

- Subjecting has any condition, including compromised pulmonary function, that would
preclude the use of lomustine.

- Subject is currently being treated with other investigational agents.

- Subject has received other investigational therapy within the last 28 days.

- Subject has received surgery within the last four weeks.

- Subject is within 12 weeks of completion of radiation.

- Subject has an active implantable or other electromagnetic device.

- Subject has a metal implant, including a programmable shunt, in the head or neck that
is incompatible with MRI.

- Subject is known to be HIV positive.

- Subject is pregnant, nursing or intends to become pregnant during the course of the
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557